Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Bmc Cancer
Wick, A A; Sander, A A; Koch, M M; Bendszus, M M; Combs, S S; Haut, T T; Dormann, A A; Walter, S S; Pertz, M M; Merkle-Lock, J J; Selkrig, N N; Limprecht, R R; Baumann, L L; Kieser, M M; Sahm, F F; Schlegel, U U; Winkler, F F; Platten, M M; Wick, W W; Kessler, T T
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
Neuro-Oncology
de la Fuente, Macarena I MI; Colman, Howard H; Rosenthal, Mark M; Van Tine, Brian A BA; Levacic, Danijela D; Walbert, Tobias T; Gan, Hui K HK; Vieito, Maria M; Milhem, Mohammed M MM; Lipford, Kathryn K; Forsyth, Sanjeev S; Guichard, Sylvie M SM; Mikhailov, Yelena Y; Sedkov, Alexander A; Brevard, Julie J; Kelly, Patrick F PF; Mohamed, Hesham H; Monga, Varun V
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.
Nature Communications
Bassal, Mahmoud A MA; Samaraweera, Saumya E SE; Lim, Kelly K; Benard, Brooks A BA; Bailey, Sheree S; Kaur, Satinder S; Leo, Paul P; Toubia, John J; Thompson-Peach, Chloe C; Nguyen, Tran T; Maung, Kyaw Ze Ya KZY; Casolari, Debora A DA; Iarossi, Diana G DG; Pagani, Ilaria S IS; Powell, Jason J; Pitson, Stuart S; Natera, Siria S; Roessner, Ute U; Lewis, Ian D ID; Brown, Anna L AL; Tenen, Daniel G DG; Robinson, Nirmal N; Ross, David M DM; Majeti, Ravindra R; Gonda, Thomas J TJ; Thomas, Daniel D; D'Andrea, Richard J RJ
Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary.
British Journal Of Cancer
Conway, Alicia-Marie AM; Morris, Georgina C GC; Smith, Sarah S; Vekeria, Monique M; Manoharan, Prakash P; Mitchell, Claire C; Backen, Alison A; Oliveira, Pedro P; Hubner, Richard A RA; Lamarca, Angela A; McNamara, Mairéad G MG; Valle, Juan W JW; Cook, Natalie N
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Acta Neuropathologica Communications
Habiba, Umma U; Sugino, Hirokazu H; Yordanova, Roumyana R; Ise, Koki K; Tanei, Zen-Ichi ZI; Ishida, Yusuke Y; Tanikawa, Satoshi S; Terasaka, Shunsuke S; Sato, Ken-Ichi KI; Kamoshima, Yuuta Y; Katoh, Masahiko M; Nagane, Motoo M; Shibahara, Junji J; Tsuda, Masumi M; Tanaka, Shinya S
Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032.
Cancers
Wenger, Katharina J KJ; Richter, Christian C; Burger, Michael C MC; Urban, Hans H; Kaulfuss, Stefan S; Harter, Patrick N PN; Sreeramulu, Sridhar S; Schwalbe, Harald H; Steinbach, Joachim P JP; Hattingen, Elke E; Bähr, Oliver O; Pilatus, Ulrich U
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Leukemia
Heuser, Michael M; Palmisiano, Neil N; Mantzaris, Ioannis I; Mims, Alice A; DiNardo, Courtney C; Silverman, Lewis R LR; Wang, Eunice S ES; Fiedler, Walter W; Baldus, Claudia C; Schwind, Sebastian S; Pardee, Timothy T; Perl, Alexander E AE; Cai, Charles C; Kaulfuss, Stefan S; Lagkadinou, Eleni E; Rentzsch, Christine C; Wagner, Markus M; Wilkinson, Gary G; Wu, Bingyan B; Jeffers, Michael M; Genvresse, Isabelle I; Krämer, Alwin A
MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia.
Nature Communications
Itskovich, Svetlana S SS; Gurunathan, Arun A; Clark, Jason J; Burwinkel, Matthew M; Wunderlich, Mark M; Berger, Mikaela R MR; Kulkarni, Aishwarya A; Chetal, Kashish K; Venkatasubramanian, Meenakshi M; Salomonis, Nathan N; Kumar, Ashish R AR; Lee, Lynn H LH
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
European Journal Of Cancer (Oxford, England : 1990)
George, Sally L SL; Izquierdo, Elisa E; Campbell, James J; Koutroumanidou, Eleni E; Proszek, Paula P; Jamal, Sabri S; Hughes, Deborah D; Yuan, Lina L; Marshall, Lynley V LV; Carceller, Fernando F; Chisholm, Julia C JC; Vaidya, Sucheta S; Mandeville, Henry H; Angelini, Paola P; Wasti, Ajla A; Bexelius, Tomas T; Thway, Khin K; Gatz, Susanne A SA; Clarke, Matthew M; Al-Lazikani, Bissan B; Barone, Giuseppe G; Anderson, John J; Tweddle, Deborah A DA; Gonzalez, David D; Walker, Brian A BA; Barton, Jack J; Depani, Sarita S; Eze, Jessica J; Ahmed, Saira W SW; Moreno, Lucas L; Pearson, Andrew A; Shipley, Janet J; Jones, Chris C; Hargrave, Darren D; Jacques, Thomas S TS; Hubank, Michael M; Chesler, Louis L
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Acs Medicinal Chemistry Letters
Zhao, Qian Q; Manning, James R JR; Sutton, James J; Costales, Abran A; Sendzik, Martin M; Shafer, Cynthia M CM; Levell, Julian R JR; Liu, Gang G; Caferro, Thomas T; Cho, Young Shin YS; Palermo, Mark M; Chenail, Gregg G; Dooley, Julia J; Villalba, Brian B; Farsidjani, Ali A; Chen, Jinyun J; Dodd, Stephanie S; Gould, Ty T; Liang, Guiqing G; Slocum, Kelly K; Pu, Minying M; Firestone, Brant B; Growney, Joseph J; Heimbach, Tycho T; Pagliarini, Raymond R
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
Bmc Genomics
Peraldo-Neia, C C; Ostano, P P; Cavalloni, G G; Pignochino, Y Y; Sangiolo, D D; De Cecco, L L; Marchesi, E E; Ribero, D D; Scarpa, A A; De Rose, A M AM; Giuliani, A A; Calise, F F; Raggi, C C; Invernizzi, P P; Aglietta, M M; Chiorino, G G; Leone, F F
Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
Cell Reports
Hollinshead, Kate E R KER; Munford, Haydn H; Eales, Katherine L KL; Bardella, Chiara C; Li, Chunjie C; Escribano-Gonzalez, Cristina C; Thakker, Alpesh A; Nonnenmacher, Yannic Y; Kluckova, Katarina K; Jeeves, Mark M; Murren, Robert R; Cuozzo, Federica F; Ye, Dan D; Laurenti, Giulio G; Zhu, Wei W; Hiller, Karsten K; Hodson, David J DJ; Hua, Wei W; Tomlinson, Ian P IP; Ludwig, Christian C; Mao, Ying Y; Tennant, Daniel A DA
Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours.
Oncotarget
Izquierdo, Elisa E; Yuan, Lina L; George, Sally S; Hubank, Michael M; Jones, Chris C; Proszek, Paula P; Shipley, Janet J; Gatz, Susanne A SA; Stinson, Caedyn C; Moore, Andrew S AS; Clifford, Steven C SC; Hicks, Debbie D; Lindsey, Janet C JC; Hill, Rebecca M RM; Jacques, Thomas S TS; Chalker, Jane J; Thway, Khin K; O'Connor, Simon S; Marshall, Lynley L; Moreno, Lucas L; Pearson, Andrew A; Chesler, Louis L; Walker, Brian A BA; De Castro, David Gonzalez DG
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.
Nature Communications
Sinha, Subarna S; Thomas, Daniel D; Chan, Steven S; Gao, Yang Y; Brunen, Diede D; Torabi, Damoun D; Reinisch, Andreas A; Hernandez, David D; Chan, Andy A; Rankin, Erinn B EB; Bernards, Rene R; Majeti, Ravindra R; Dill, David L DL
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Acs Medicinal Chemistry Letters
Levell, Julian R JR; Caferro, Thomas T; Chenail, Gregg G; Dix, Ina I; Dooley, Julia J; Firestone, Brant B; Fortin, Pascal D PD; Giraldes, John J; Gould, Ty T; Growney, Joseph D JD; Jones, Michael D MD; Kulathila, Raviraj R; Lin, Fallon F; Liu, Gang G; Mueller, Arne A; van der Plas, Simon S; Slocum, Kelly K; Smith, Troy T; Terranova, Remi R; Touré, B Barry BB; Tyagi, Viraj V; Wagner, Trixie T; Xie, Xiaoling X; Xu, Ming M; Yang, Fan S FS; Zhou, Liping X LX; Pagliarini, Raymond R; Cho, Young Shin YS
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
The Oncologist
Goyal, Lipika L; Govindan, Aparna A; Sheth, Rahul A RA; Nardi, Valentina V; Blaszkowsky, Lawrence S LS; Faris, Jason E JE; Clark, Jeffrey W JW; Ryan, David P DP; Kwak, Eunice L EL; Allen, Jill N JN; Murphy, Janet E JE; Saha, Supriya K SK; Hong, Theodore S TS; Wo, Jennifer Y JY; Ferrone, Cristina R CR; Tanabe, Kenneth K KK; Chong, Dawn Q DQ; Deshpande, Vikram V; Borger, Darrell R DR; Iafrate, A John AJ; Bardeesy, Nabeel N; Zheng, Hui H; Zhu, Andrew X AX
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Leukemia
Molenaar, R J RJ; Thota, S S; Nagata, Y Y; Patel, B B; Clemente, M M; Przychodzen, B B; Hirsh, C C; Viny, A D AD; Hosano, N N; Bleeker, F E FE; Meggendorfer, M M; Alpermann, T T; Shiraishi, Y Y; Chiba, K K; Tanaka, H H; van Noorden, C J F CJ; Radivoyevitch, T T; Carraway, H E HE; Makishima, H H; Miyano, S S; Sekeres, M A MA; Ogawa, S S; Haferlach, T T; Maciejewski, J P JP
IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.
Neuro-Oncology
Leu, Severina S; von Felten, Stefanie S; Frank, Stephan S; Vassella, Erik E; Vajtai, Istvan I; Taylor, Elisabeth E; Schulz, Marianne M; Hutter, Gregor G; Hench, Jürgen J; Schucht, Philippe P; Boulay, Jean-Louis JL; Mariani, Luigi L
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Journal Of Molecular Medicine (Berlin, Germany)
Kalinina, Juliya J; Carroll, Anne A; Wang, Liya L; Yu, Qiqi Q; Mancheno, Danny E DE; Wu, Shaoxiong S; Liu, Frank F; Ahn, Jun J; He, Miao M; Mao, Hui H; Van Meir, Erwin G EG